Connor McGuire, Sean Nurmsoo, Osama A Samargandi, Michael Bezuhly
{"title":"氨甲环酸在初次择期鼻整形术中减少术中出血量和术后水肿及瘀斑中的作用:一项系统综述和荟萃分析。","authors":"Connor McGuire, Sean Nurmsoo, Osama A Samargandi, Michael Bezuhly","doi":"10.1001/jamafacial.2018.1737","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Blood loss from surgical procedures is a major issue worldwide as the demand for blood products is increasing. Tranexamic acid is an antifibrinolytic agent commonly used to reduce intraoperative blood loss.</p><p><strong>Objective: </strong>To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.</p><p><strong>Data sources: </strong>A systematic review and meta-analysis was undertaken in an academic medical setting using Medline, Embase, and Google Scholar from inception to June 30, 2018. All references of included articles were screened for potential inclusion. The search was mapped to Medical Subject Headings, and the following terms were used to identify potential articles: reconstruction or rhinoplasty and tranexamic acid or anti-fibrinolysis or antifibrinolysis and bleeding or ecchymosis or bruising or edema or complications.</p><p><strong>Study selection: </strong>The population of interest consisted of adult patients undergoing primary elective rhinoplasty. The intervention was the use of tranexamic acid. The control group was composed of patients receiving a placebo. Primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis. In vitro or animal studies were excluded, and only English-language articles were included.</p><p><strong>Data extraction and synthesis: </strong>The PRISMA guidelines were followed, and articles were assessed using the Cochrane Collaboration's tool for assessing risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Random-effects meta-analysis was performed to determine the overall effect size.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis.</p><p><strong>Results: </strong>Five studies (comprising 332 patients) were included in the qualitative analysis, all of which were randomized clinical trials published within the past 5 years. The mean (SD) patient age was 27 (7) years (age range, 16-42 years), while the mean (SD) sample size was 66 (19) (range, 50-96). Meta-analysis of 4 studies (271 patients) indicated that tranexamic acid treatment resulted in a mean reduction in intraoperative blood loss of -41.6 mL (95% CI, -69.8 to -13.4 mL) compared with controls (P = .004). Three studies indicated that postoperative edema and ecchymosis were reduced with tranexamic acid treatment compared with controls; however, there was no significant difference compared with corticosteroid use. Four studies were considered of high methodological quality, with a low risk of bias. The overall quality of evidence was high.</p><p><strong>Conclusions and relevance: </strong>Tranexamic acid has the ability to significantly reduce intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.</p><p><strong>Level of evidence: </strong>4.</p>","PeriodicalId":14538,"journal":{"name":"JAMA facial plastic surgery","volume":"21 3","pages":"191-198"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/jamafacial.2018.1737","citationCount":"28","resultStr":"{\"title\":\"Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis.\",\"authors\":\"Connor McGuire, Sean Nurmsoo, Osama A Samargandi, Michael Bezuhly\",\"doi\":\"10.1001/jamafacial.2018.1737\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Blood loss from surgical procedures is a major issue worldwide as the demand for blood products is increasing. Tranexamic acid is an antifibrinolytic agent commonly used to reduce intraoperative blood loss.</p><p><strong>Objective: </strong>To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.</p><p><strong>Data sources: </strong>A systematic review and meta-analysis was undertaken in an academic medical setting using Medline, Embase, and Google Scholar from inception to June 30, 2018. All references of included articles were screened for potential inclusion. The search was mapped to Medical Subject Headings, and the following terms were used to identify potential articles: reconstruction or rhinoplasty and tranexamic acid or anti-fibrinolysis or antifibrinolysis and bleeding or ecchymosis or bruising or edema or complications.</p><p><strong>Study selection: </strong>The population of interest consisted of adult patients undergoing primary elective rhinoplasty. The intervention was the use of tranexamic acid. The control group was composed of patients receiving a placebo. Primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis. In vitro or animal studies were excluded, and only English-language articles were included.</p><p><strong>Data extraction and synthesis: </strong>The PRISMA guidelines were followed, and articles were assessed using the Cochrane Collaboration's tool for assessing risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Random-effects meta-analysis was performed to determine the overall effect size.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis.</p><p><strong>Results: </strong>Five studies (comprising 332 patients) were included in the qualitative analysis, all of which were randomized clinical trials published within the past 5 years. The mean (SD) patient age was 27 (7) years (age range, 16-42 years), while the mean (SD) sample size was 66 (19) (range, 50-96). Meta-analysis of 4 studies (271 patients) indicated that tranexamic acid treatment resulted in a mean reduction in intraoperative blood loss of -41.6 mL (95% CI, -69.8 to -13.4 mL) compared with controls (P = .004). Three studies indicated that postoperative edema and ecchymosis were reduced with tranexamic acid treatment compared with controls; however, there was no significant difference compared with corticosteroid use. Four studies were considered of high methodological quality, with a low risk of bias. The overall quality of evidence was high.</p><p><strong>Conclusions and relevance: </strong>Tranexamic acid has the ability to significantly reduce intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.</p><p><strong>Level of evidence: </strong>4.</p>\",\"PeriodicalId\":14538,\"journal\":{\"name\":\"JAMA facial plastic surgery\",\"volume\":\"21 3\",\"pages\":\"191-198\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1001/jamafacial.2018.1737\",\"citationCount\":\"28\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA facial plastic surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jamafacial.2018.1737\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA facial plastic surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jamafacial.2018.1737","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 28
摘要
重要性:随着对血液制品的需求不断增加,外科手术失血是世界范围内的一个主要问题。氨甲环酸是一种抗纤溶剂,常用于减少术中失血。目的:系统探讨氨甲环酸在初次择期鼻整形术中减少术中出血量和术后水肿瘀斑的作用。数据来源:从开始到2018年6月30日,使用Medline、Embase和Google Scholar在学术医疗环境中进行了系统评价和荟萃分析。对纳入文章的所有参考文献进行筛选,以确定是否可能纳入。搜索被映射到医学主题标题,并使用以下术语来识别潜在的文章:重建或鼻整形和氨甲环酸或抗纤溶或抗纤溶和出血或瘀斑或挫伤或水肿或并发症。研究选择:研究对象包括接受初级择期鼻整形手术的成年患者。干预措施是使用氨甲环酸。对照组由服用安慰剂的患者组成。主要结局是术中失血和术后水肿和瘀斑。排除体外或动物研究,仅纳入英文文章。数据提取和综合:遵循PRISMA指南,使用Cochrane协作的偏倚风险评估工具和推荐评估、发展和评估分级(GRADE)指南对文章进行评估。随机效应荟萃分析确定总体效应大小。主要观察指标:主要观察指标为术中出血量和术后水肿瘀斑。结果:定性分析纳入5项研究(共332例患者),均为近5年内发表的随机临床试验。患者平均年龄(SD)为27(7)岁(年龄范围16-42岁),平均样本量(SD)为66(19)岁(年龄范围50-96)。4项研究(271例患者)的荟萃分析表明,与对照组相比,氨甲环酸治疗导致术中出血量平均减少-41.6 mL (95% CI, -69.8至-13.4 mL) (P = 0.004)。三项研究表明,与对照组相比,氨甲环酸治疗可减轻术后水肿和瘀斑;然而,与皮质类固醇的使用相比,没有显著差异。四项研究被认为具有高方法学质量,偏倚风险低。证据的总体质量很高。结论及意义:氨甲环酸能够显著减少初次择期鼻整形患者术中出血量和术后水肿瘀斑。证据等级:4。
Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis.
Importance: Blood loss from surgical procedures is a major issue worldwide as the demand for blood products is increasing. Tranexamic acid is an antifibrinolytic agent commonly used to reduce intraoperative blood loss.
Objective: To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.
Data sources: A systematic review and meta-analysis was undertaken in an academic medical setting using Medline, Embase, and Google Scholar from inception to June 30, 2018. All references of included articles were screened for potential inclusion. The search was mapped to Medical Subject Headings, and the following terms were used to identify potential articles: reconstruction or rhinoplasty and tranexamic acid or anti-fibrinolysis or antifibrinolysis and bleeding or ecchymosis or bruising or edema or complications.
Study selection: The population of interest consisted of adult patients undergoing primary elective rhinoplasty. The intervention was the use of tranexamic acid. The control group was composed of patients receiving a placebo. Primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis. In vitro or animal studies were excluded, and only English-language articles were included.
Data extraction and synthesis: The PRISMA guidelines were followed, and articles were assessed using the Cochrane Collaboration's tool for assessing risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Random-effects meta-analysis was performed to determine the overall effect size.
Main outcomes and measures: The primary outcomes were intraoperative blood loss and postoperative edema and ecchymosis.
Results: Five studies (comprising 332 patients) were included in the qualitative analysis, all of which were randomized clinical trials published within the past 5 years. The mean (SD) patient age was 27 (7) years (age range, 16-42 years), while the mean (SD) sample size was 66 (19) (range, 50-96). Meta-analysis of 4 studies (271 patients) indicated that tranexamic acid treatment resulted in a mean reduction in intraoperative blood loss of -41.6 mL (95% CI, -69.8 to -13.4 mL) compared with controls (P = .004). Three studies indicated that postoperative edema and ecchymosis were reduced with tranexamic acid treatment compared with controls; however, there was no significant difference compared with corticosteroid use. Four studies were considered of high methodological quality, with a low risk of bias. The overall quality of evidence was high.
Conclusions and relevance: Tranexamic acid has the ability to significantly reduce intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty.
期刊介绍:
Facial Plastic Surgery & Aesthetic Medicine (Formerly, JAMA Facial Plastic Surgery) is a multispecialty journal with a key mission to provide physicians and providers with the most accurate and innovative information in the discipline of facial plastic (reconstructive and cosmetic) interventions.